Research Topics

• Clinical trials in the treatment of cytomegalovirus retinitis
• Epidemiology of ocular complications of AIDS
• Cytomegalovirus drug resistance
  
  
  

• Ocular complications of AIDS
• Treatment of cytomegalovirus retinitis
• Cytomegalovirus and viral resistance
  
  
  

Dr Jabs is Professor and Chairman of the Department of Ophthalmology at the Mount Sinai School of Medicine.


Committees and Organizations

• Committee on Guidelines for the Prevention of Opportunistic Infections in Patients with HIV, USPHS/IDSA
  
  
  

• Clinician Scientist Award, The Johns Hopkins University (1986 and 1987)
• Olga Keith Weiss Scholar Award, Research to Prevent Blindness (1991)
• Sjögren's Syndrome Foundation Ethel-Baxter Award (1995)
• Lew R. Wasserman Merit Award, Research to Prevent Blindness (1997)
  
  
  

• Dartmouth College, AB, Chemistry (1973)
• The Johns Hopkins University School of Medicine, MD (1977)
• The Wilmer Eye Institute, The Johns Hopkins University and Hospital, Residency in Ophthalmology (1978)
• The Johns Hopkins Hospital, Residency in Internal Medicine (1983)
• The Johns Hopkins Medical Institutions, Fellowship in Rheumatology (1984)
• The Johns Hopkins University, School of Continuing Studies, MS in Business, Medical Services Management (1998)
• The Johns Hopkins University, School of Graduate Studies in Business and Education, MBA (1999)
  
  
  

1. Jabs DA. Ocular manifestations of HIV infection. Trans Am Ophthalmol Soc. 1995;93:623-683.
2. Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol. 1998;126:817-822.
3. Nguyen QD, Kempen JH, Bolton SG, Dunn JP, Jabs DA. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis following highly active antiretroviral therapy. Am J Ophthalmol. 2000;129:634-639.
4. Kempen JH, Jabs DA, Dunn JP, West SK, Tonascia J. Retinal detachment risk in cytomegalovirus retinitis related to the acquired immune deficiency syndrome. Arch Ophthalmol. 2001;119:33-40.
5. Hu H, Jabs DA, Forman MS, Martin BK, Dunn JP, Weinberg DV, Davis JL; Cytomegalovirus Retinitis and Viral Resistance Study Group. Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J Infect Dis. 2002;185:861-867.
6. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia JA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. 2003;121:466-476.
7. Kempen JH, Jabs DA, Wilson LA, Dunn JP, West SK, Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis. 2003;37:1365-1373.
8. Weinberg A, Jabs DA, Chou S, Martin BK, Lurain NS, Forman MS, Crumpacker C. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis. 2003;187:777-784.
9. Jabs DA, Martin BK, Forman MS, Hubbard L, Dunn JP, Kempen JH, Davis JL, Weinberg DV; Cytomegalovirus Retinitis and Viral Resistance Study Group. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol. 2003;135:26-34.
10. Jabs DA. AIDS and ophthalmology in 2004. Arch Ophthalmol. 2004;122:1040-1042.